Literature DB >> 21057786

Reversible brain hypometabolism associated with central nervous system systemic lupus erythematosus.

Jukka Kemppainen1, Sami Kajander, Timo Yli-Kerttula, Laura Airas, Marko Seppänen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057786     DOI: 10.1007/s00259-010-1652-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus.

Authors:  C H Kao; J L Lan; S P ChangLai; K K Liao; R F Yen; P U Chieng
Journal:  Eur J Nucl Med       Date:  1999-02

2.  Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study.

Authors:  A Otte; S M Weiner; H H Peter; J Mueller-Brand; M Goetze; E Moser; J Gutfleisch; S Hoegerle; F D Juengling; E U Nitzsche
Journal:  Eur J Nucl Med       Date:  1997-07

3.  Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus.

Authors:  M Sailer; W Burchert; C Ehrenheim; H G Smid; J Haas; K Wildhagen; U Wurster; H Deicher
Journal:  J Neurol       Date:  1997-03       Impact factor: 4.849

4.  Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.

Authors:  S M Weiner; A Otte; M Schumacher; R Klein; J Gutfleisch; I Brink; P Otto; E U Nitzsche; E Moser; H H Peter
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

5.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

Authors:  S Minoshima; K A Frey; R A Koeppe; N L Foster; D E Kuhl
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.